INGN logo

Inogen, Inc. Stock Price

NasdaqGS:INGN Community·US$172.7m Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

INGN Share Price Performance

US$6.30
0.17 (2.77%)
US$12.67
Fair Value
US$6.30
0.17 (2.77%)
50.3% undervalued intrinsic discount
US$12.67
Fair Value
Price US$6.30
AnalystConsensusTarget US$12.67
AnalystLowTarget US$12.00
AnalystHighTarget US$14.00

INGN Community Narratives

·
Fair Value US$12.67 50.3% undervalued intrinsic discount

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

0users have liked this narrative
2users have commented on this narrative
6users have followed this narrative
·
Fair Value US$12 47.5% undervalued intrinsic discount

Pricing Pressures And Rivals Will Erode Portable Oxygen Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$14 55.0% undervalued intrinsic discount

Aging Global Population And At-Home Care Will Boost Market Demand

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$12
47.5% undervalued intrinsic discount
Profit Margin
12.7%
Future PE
7.65x
Price in 2029
US$14.96
US$14
55.0% undervalued intrinsic discount
Profit Margin
12.32%
Future PE
11.21x
Price in 2028
US$17.36

Trending Discussion

Updated Narratives

INGN logo

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Fair Value: US$12.67 50.3% undervalued intrinsic discount
6 users have set this as their fair value
2 users have commented on this narrative
0 users have liked this narrative
INGN logo

INGN: Buybacks And New Leadership Will Support Future Returns

Fair Value: US$12 47.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INGN logo

Aging Global Population And At-Home Care Will Boost Market Demand

Fair Value: US$14 55.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with excellent balance sheet.

1 Risk
3 Rewards

Inogen, Inc. Key Details

US$351.5m

Revenue

US$195.7m

Cost of Revenue

US$155.8m

Gross Profit

US$180.7m

Other Expenses

-US$24.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.92
44.31%
-7.08%
0%
View Full Analysis

About INGN

Founded
2001
Employees
753
CEO
Kevin R. Smith
WebsiteView website
www.provider.inogen.com

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.

Recent INGN News & Updates

Narrative Update May 09

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Analysts have trimmed their price target on Inogen from about $13.00 to roughly $12.67, reflecting updated assumptions around revenue, profit margins and future P/E following fresh bullish initiation research from the Street. Analyst Commentary Analysts are using the fresh bullish initiation as a chance to refresh their models, focus on execution and reassess how much they are willing to pay for Inogen at the current P/E.

Recent updates

No updates